AZD5904
Based on 14 publication(s) in Google Scholar
AZD5904 is a selective and irreversible inhibitor of human Myeloperoxidase (MPO) with an IC50 of 140 nM and has similar potency in mouse and rat.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.93%
- No. CAS: 618913-30-7
- Fòrmula: C10H12N4O2S
- Peso molecular:252.29
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Clinical Compound Library
HY-L026
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Oxygen Sensing Compound Library
HY-L045
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Metabolic Enzyme Compound Library
HY-L146
-
Highly Selective Inhibitors Library
HY-L158
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
3D Diverse Fragment Library
HY-L903
Publications Citing Use of MedChemExpress (MCE) AZD5904
More- Cancer Res. 2019 Oct 15;79(20):5191-5203. [Abstract]
- Adv Sci (Weinh). 2026 Apr;13(24):e19500. [Abstract]
- Leukemia. 2022 Aug;36(8):2086-2096. [Abstract]
- Redox Biol. 2023 Nov:67:102905. [Abstract]
- J Immunother Cancer. 2023 Feb;11(2):e005837. [Abstract]
- Burns Trauma. 2021 Sep 17:9:tkab030. [Abstract]
- Cancer Immunol Immunother. 2024 Feb 17;73(3):57. [Abstract]
- J Cell Mol Med. 2022 Apr;26(7):2089-2103. [Abstract]
- Neurocrit Care. 2025 Jun;42(3):945-952. [Abstract]
- BMC Immunol. 2022 Nov 15;23(1):55. [Abstract]
- SSRN. 2025 Feb 20.
- Res Sq. 2024 Jul 18.
- Research Square Print. September 6th, 2022.
- Research Square Print. 2022 Aug.
Customer Validation & Images
-
WB
Actividad biológica
IC50: 140 nM (human MPO)[1]
AZD5904 is a pselective and irreversible inhibitor of human Myeloperoxidase (MPO) with an IC50 of 140 nM and has similar potency in mouse and rat. It is 10 to 19-fold selective compare to the closely related lactoperoxidase and thyroid peroxidase; >70-fold to a broad panel of other enzymes, ion channels, and receptors[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 618913-30-7
-
Appearance Solid
-
Peso molecular 252.29
-
Fòrmula C10H12N4O2S
-
Color White to yellow
-
SMILES
O=C1NC(N(C[C@@H]2OCCC2)C3=C1N=CN3)=S
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (14)
-
Journal Impact Factor
-
Most Recent
-
Cancer Res
Targeting Myeloperoxidase Disrupts Mitochondrial Redox Balance and Overcomes Cytarabine Resistance in Human Acute Myeloid Leukemia. [Abstract]2019 Oct 15;79(20):5191-5203. PMID: 31358527 -
Adv Sci (Weinh)
Diabetes Mellitus Facilitates Gallstone Formation Through CXCR2-NETs-Mediated Liver-Bile Barrier Damage. [Abstract]2026 Apr;13(24):e19500. PMID: 41698066 -
Leukemia
2022 Aug;36(8):2086-2096. PMID: 35761024 -
Redox Biol
VEO-IBD NOX1 variant highlights a structural region essential for NOX/DUOX catalytic activity. [Abstract]2023 Nov:67:102905. PMID: 37820403 -
J Immunother Cancer
2023 Feb;11(2):e005837. PMID: 36805920 -
Burns Trauma
Neutrophil-derived heparin binding protein triggers vascular leakage and synergizes with myeloperoxidase at the early stage of severe burns (With video). [Abstract]2021 Sep 17:9:tkab030. PMID: 34646891 -
Cancer Immunol Immunother
Targeting myeloperoxidase limits myeloid cell immunosuppression enhancing immune checkpoint therapy for pancreatic cancer. [Abstract]2024 Feb 17;73(3):57. PMID: 38367056 -
J Cell Mol Med
CD44/ERM/F-actin complex mediates targeted nuclear degranulation and excessive neutrophil extracellular trap formation during sepsis. [Abstract]2022 Apr;26(7):2089-2103. PMID: 35146909 -
Neurocrit Care
Small Molecule Myeloperoxidase (MPO) Inhibition Prevents Delayed Cerebral Injury (DCI) After Subarachnoid Hemorrhage (SAH) in a Murine Model. [Abstract]2025 Jun;42(3):945-952. PMID: 39653978 -
BMC Immunol
CD206+CD68+ mono-macrophages and serum soluble CD206 level are increased in antineutrophil cytoplasmic antibodies associated glomerulonephritis. [Abstract]2022 Nov 15;23(1):55. PMID: 36376784
AZD5904 purchased from MedChemExpress. Usage Cited in: BMC Immunol. 2022 Nov 15;23(1):55. [Abstract]
AZD5904 signifcantly reduces CD206 expression by inhibiting MPO in BMDMs.
-
-
-
-
Solvente y solubilidad
DMSO : 50 mg/mL (198.18 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (8.24 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (279 KB)
-
SDS (418 KB)
- English - EN (418 KB)
- Français - FR (418 KB)
- Deutsch - DE (418 KB)
- Norwegian - NO (418 KB)
- Español - ES (418 KB)
- Swedish - SV (418 KB)
- Italian - IT (418 KB)
- Korean - KR (418 KB)
- Portuguese - PT (418 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Myeloperoxidase (MPO) inhibitor.
[2]. Tidén AK, Sjögren T, Svensson M, et al. 2-thioxanthines are mechanism-based inactivators of myeloperoxidase that block oxidative stress during inflammation. J Biol Chem. 2011;286(43):37578-37589. [Content Brief]
[3]. Chai W, Aylor K, Liu Z, Gan LM, Michaëlsson E, Barrett E. Inhibiting myeloperoxidase prevents onset and reverses established high-fat diet-induced microvascular insulin resistance. Am J Physiol Endocrinol Metab. 2019;317(6):E1063-E1069. [Content Brief]
[4]. Ramachandra CJA, Kp MMJ, Chua J, et al. Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes. Cardiovasc Res. 2022;118(2):517-530. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.9637 mL | 19.8185 mL | 39.6369 mL | 99.0923 mL |
| 5 mM | 0.7927 mL | 3.9637 mL | 7.9274 mL | 19.8185 mL | |
| 10 mM | 0.3964 mL | 1.9818 mL | 3.9637 mL | 9.9092 mL | |
| 15 mM | 0.2642 mL | 1.3212 mL | 2.6425 mL | 6.6062 mL | |
| 20 mM | 0.1982 mL | 0.9909 mL | 1.9818 mL | 4.9546 mL | |
| 25 mM | 0.1585 mL | 0.7927 mL | 1.5855 mL | 3.9637 mL | |
| 30 mM | 0.1321 mL | 0.6606 mL | 1.3212 mL | 3.3031 mL | |
| 40 mM | 0.0991 mL | 0.4955 mL | 0.9909 mL | 2.4773 mL | |
| 50 mM | 0.0793 mL | 0.3964 mL | 0.7927 mL | 1.9818 mL | |
| 60 mM | 0.0661 mL | 0.3303 mL | 0.6606 mL | 1.6515 mL | |
| 80 mM | 0.0495 mL | 0.2477 mL | 0.4955 mL | 1.2387 mL | |
| 100 mM | 0.0396 mL | 0.1982 mL | 0.3964 mL | 0.9909 mL |
AZD5904 Related Classifications
HY-111341 Related Classifications
Powered by Bioz